Lv4
518 积分 2024-07-10 加入
Glofitamab stimulates immune cell infiltration of CNS tumors and induces clinical responses in secondary CNS lymphoma
9小时前
待确认
Bispecific Antibodies and Autologous Chimeric Antigen Receptor T cell therapies for Treatment of Hematological Malignancies
14小时前
已完结
Mechanisms of resistance against T-cell engaging bispecific antibodies in multiple myeloma: implications for novel treatment strategies
21小时前
已完结
Extremely potent, rapid and costimulation‐independent cytotoxic T‐cell response against lymphoma cells catalyzed by a single‐chain bispecific antibody
2天前
已完结
Role of naive and memory T cells in tumor cell lysis mediated by Bi-specific antibodies
2天前
已完结
Glofitamab in refractory or relapsed diffuse large B cell lymphoma after failing CAR-T cell therapy: a phase 2 LYSA study
2天前
已完结
Emerging biomarkers for CD3×CD20 bispecific antibodies in lymphoma
2天前
已完结
Relapse after glofitamab has a poor prognosis and rates of CD20 loss are high
2天前
已完结
Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study
5天前
已完结
Three-year cardiovascular and non-cardiovascular adverse events in patients with chronic lymphocytic leukemia or small cell lymphocytic lymphoma treated with Bruton tyrosine kinase inhibitors acalabrutinib or ibrutinib: a real-world analysis
8天前
已完结
皖公网安备34019202002308
